T-cell immune checkpoint inhibitors are most common and successful agents used in cancer immunotherapy (6), which would activate the immune system through targeting cancer immune checkpoints such as PD-1/PD-L1, CTLA-4, and block immunosuppression signals (7). This evidence concerns the gene CTLA4 and cancer.